Lexicon Pharmaceuticals Sets Sights on Heart Trial Results, Diabetes Drug Resubmission in 2027
Lexicon Pharmaceuticals (LXRX) expects results from a heart trial and plans to resubmit sotagliflozin for type 1 diabetes in Q1 2027. The company aims for FDA approval in 2027, with safety data from the STENO1 study addressing DKA concerns. Lexicon also plans to market the drug for hypertrophic cardiomyopathy (HCM) separately, with its own pricing and branding.




